FDA Import Refusal 1FX-7136262-8/10001/1 — AstraZeneca Pharmaceuticals LP
The FDA refused shipment 1FX-7136262-8/10001/1 from AstraZeneca Pharmaceuticals LP (United States) on Aug 25, 2026. The refused product falls under Drugs and Biologics — DAPAGLIFLOZIN (ANTI-DIABETIC). Cited charge: 75 This firm has 5 or more other import refusals on record.
Refusal Details
- Date
- Aug 25, 2026
- Country
- United States
- Product Category
- Drugs and Biologics
- Product Code
- 61PCY70 DAPAGLIFLOZIN (ANTI-DIABETIC)
- Charges
- 75